Asunto(s)
Anticuerpos Antinucleares/sangre , Anticuerpos Antinucleares/inmunología , Enfermedades Autoinmunes/sangre , Enfermedades Autoinmunes/diagnóstico , Pruebas Diagnósticas de Rutina/normas , Implementación de Plan de Salud , Enfermedades Autoinmunes/inmunología , Automatización , Técnica del Anticuerpo Fluorescente Indirecta , HumanosRESUMEN
OBJECTIVES: Isolated acquired factor VII (FVII) deficiency is a rare haemorrhagic disorder. We report what is currently known about the pathogenesis, clinical features, diagnosis, treatment and prognosis of acquired FVII deficiency. METHODS: We performed a literature search and included all articles published between 1980 and August 2015. RESULTS AND CONCLUSIONS: Acquired FVII deficiency has been reported in 42 patients. There are well-established clinical diseases associated with acquired FVII deficiency, most notably infections, malignancy and haematological stem cell transplantation. The exact pathogenesis of the diseases is still unknown, but different pathophysiological hypotheses have been suggested. The clinical manifestation of acquired FVII deficiency varies greatly in severity; asymptomatic course as well as severe life-threatening bleeding diathesis and fatal bleedings have been described.
Asunto(s)
Deficiencia del Factor VII , Deficiencia del Factor VII/complicaciones , Deficiencia del Factor VII/diagnóstico , Deficiencia del Factor VII/fisiopatología , Deficiencia del Factor VII/terapia , Factor VIIa/uso terapéutico , Femenino , Trasplante de Células Madre Hematopoyéticas , Hemorragia/etiología , Humanos , Infecciones/complicaciones , Masculino , Neoplasias/complicaciones , Pronóstico , Vitamina K/uso terapéuticoAsunto(s)
Anticoagulantes/farmacología , Inhibidores del Factor Xa/farmacología , Vitamina K/antagonistas & inhibidores , Anticoagulantes/química , Coagulación Sanguínea/efectos de los fármacos , Pruebas de Coagulación Sanguínea , Inhibidores del Factor Xa/química , Humanos , Tiempo de Tromboplastina ParcialRESUMEN
For the determination of the in vitro cytochrome P450 activity in microsomes, a quantification method for the probe metabolites, formed during incubation, is required. Due to insufficient sensitivity of a previously developed high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for some of the metabolites, a fast and easy derivatization method with pyridine-3-sulfonyl chloride (PS) is described. Acetaminophen (CYP1A2), dextrorphan (CYP2D6), hydroxy-chlorzoxazone (CYP2E1) and hydroxy-mephenytoin (CYP2C19) can be derivatized because of the presence of a phenolic OH, whereas hydroxy-midazolam (CYP3A4) and hydroxy-tolbutamide (CYP2C9) remain unchanged. As PS improves the ionization efficiency in the positive electrospray ionization (ESI) mode, the sensitivity of the detection is improved significantly and meets requirements for the activity determination. Native negative electrospray type molecules, moreover, become positive ESI candidates. The direct derivatization in the aqueous incubation medium, without any other sample pre-treatment steps, such as evaporation or extraction, makes this procedure easy to perform. The method using 20s microwave irradiation was shown to equal a 10min reaction in a 60°C heating block, consequently simplifying and shortening the process. Collision induced fragmentation of the derivatives resulted in at least one native compound, rather than derivative, specific product ion, thereby improving the selectivity of the method in the multiple reaction monitoring mode. The HPLC-MS/MS method was validated, and was demonstrated to be sensitive, selective, precise and accurate. The absence of a relative matrix effect was established, notwithstanding that an absolute matrix effect was observed. The analysis of a sample after microsomal incubation, from which some of the metabolites could not be quantified using the method without derivatization, proved the usefulness of the method.